Planned Parenthood Applauds FDA Approval of Lybrel
For Immediate Release: Jan. 30, 2014
Continuous Birth Control Pill Gives Women New Hormonal Contraceptive Option
NEW YORK CITY — Planned Parenthood Federation of America (PPFA) applauded the U.S. Food and Drug Administration (FDA) approval today of Lybrel, the only pill designed to be taken daily without placebo reminder pills, 365 days a year. When used consistently and correctly, Lybrel completely suppresses the menstrual cycle, is up to 99.7 percent effective at preventing unintended pregnancy, and offers many women relief from menstrual cramps, headaches, and other discomforts associated with periods.
PPFA Vice President for Medical Affairs Vanessa Cullins, M.D., issued the following statement about Lybrel:
"FDA approval of Lybrel is great news for women who want or need to safely suppress their menstrual cycle, and now they have the convenience of a full year's birth control prescription to do it.
"At Planned Parenthood we know every woman's birth control needs are different, and the best methods are those that fit a woman's lifestyle and meet her needs — including safety, effectiveness, affordability, and reversibility. Lybrel is a good hormonal birth control option for women who don’t want to have a period every month. We are pleased to see a new, safe, and effective birth control option for women on the market."